|
Treatment outcome of AL and AS/AQ at D28. |
||||||||
| Study site |
Drug used |
Enrolled |
Parasitaemic patients on D0 N (%) |
Patients seen at D28 N (%) |
Crude parasitological failure (%) |
Geometric mean parasite density D28 (p/μl) |
PCR adjusted failure rate* |
PCR adjusted cure rate |
|
|
||||||||
| Badeku & Ojoku/Ajia Nigeria |
AL |
432 |
306 (70.8%) C.I. 67%–75% |
184 (60.1%) |
77/184 (41.8%) C.I. 35%–49% |
2835 |
14/154 (9.1%) |
90.9% C.I. 86%–95% |
| Ejisu-Juaben, Ghana |
AS/AQ |
848 |
603 (71.1%) C.I. 68%–74% |
205 (34%) |
57/205 (27.8%) C.I. 22%–34% |
15080 |
17/197 (8.6%) |
91.4% C.I. 87%–95% |
| Bugiri, Uganda |
AL |
460 |
280 (60.9%) C.I. 56%–65% |
217 (77.5%) |
8/217 (3.7%) C.I. 1.2%–6.2% |
N/A |
6/216 (2.8%) |
97.2% C.I. 95%–99% |
|
*= Samples that could not be classified by PCR were excluded from the analysis AL = artemether-lumefantrine AS/AQ = artesunate-amodiaquine | ||||||||
Ajayi et al. Malaria Journal 2008 7:190 doi:10.1186/1475-2875-7-190 |
||||||||